利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1431 条记录 (耗时 0.065 秒)

    Process for preparing isocyanate homopolymers containing uretdione groups
    44.
    发明授权
    Process for preparing isocyanate homopolymers containing uretdione groups 有权
    制备含有脲二酮基团的异氰酸酯均聚物的方法

    公开(公告)号：US09518142B2

    公开(公告)日：2016-12-13

    申请号：US14907153

    申请日：2014-03-03

    申请人： Wanhua Chemical (Ningbo) Co., Ltd. ,  Wanhua Chemical Group Co., Ltd.

    发明人： Lidong Sun

    IPC分类号： C08G18/02 ,  C08G18/16 ,  C07F9/54

    CPC分类号： C08G18/027 ,  C07F9/5414 ,  C08G18/168

    摘要： The present invention relates to a process for preparing isocyanate homopolymers containing uretdione groups, in which the phosphinoboron compound of formula (I) are used as catalysts to catalyze the homopolymerization reaction of raw isocyanates, thereby obtaining a solution of isocyanate homopolymers having uretdione groups, then separating the solution and thus obtaining the isocyanate homopolymers containing uretdione groups. The isocyanate homopolymers containing uretdione groups prepared by this process have a high amount of the uretdione groups, wherein the dependence of the amount on the conversion rate of raw isocyanates is significantly ameliorated, with low chromaticities.

    Modified creatine compounds
    46.
    发明授权
    Modified creatine compounds 有权
    改性肌酸化合物

    公开(公告)号：US09434753B2

    公开(公告)日：2016-09-06

    申请号：US14345503

    申请日：2012-09-18

    申请人： Gencia Corporation

    发明人： Shaharyar M. Khan ,  Robert Gadwood ,  Arthur Glenn Romero

    IPC分类号： C07F9/54 ,  C07F9/655 ,  C07F9/6506 ,  C07F9/22

    CPC分类号： C07F9/5456 ,  C07F9/22 ,  C07F9/5442 ,  C07F9/6506 ,  C07F9/6552

    摘要： The invention discloses creatine derivatives that are represented by Formula (I), Formula (II), and Formula (III); wherein Z is a functional group; Y is a mitochondrial targeting agent, a cationic ammonium group, or a polypeptide containing at least one positively charged amino acid residue; each R1 is independently hydrogen, alkyl, or a phosphate group; R2 a linker; R3 is a spacer group; R4 is hydrogen, alkyl, aryl, or heterocyclic; or R4 and R1, or R4 and R3, together with the nitrogen atoms to which they are attached form a heterocyclic ring, and W is hydrogen or alkyl.

    NUCLEOSIDE ANALOG SALTS WITH IMPROVED SOLUBILITY AND METHODS OF FORMING SAME
    50.
    发明申请
    NUCLEOSIDE ANALOG SALTS WITH IMPROVED SOLUBILITY AND METHODS OF FORMING SAME 审中-公开
    具有改进的溶解性的核苷类似物盐和其形成方法

    公开(公告)号：US20160002240A1

    公开(公告)日：2016-01-07

    申请号：US14770655

    申请日：2014-03-17

    申请人： THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA

    发明人： Robin D. Rogers

    IPC分类号： C07D473/18 ,  C07C309/17 ,  C07F9/54 ,  C07C215/40 ,  C07C211/63

    CPC分类号： C07D473/18 ,  A61K31/522 ,  A61K47/541 ,  C07C211/63 ,  C07C215/40 ,  C07C309/17 ,  C07F9/5407

    摘要： Disclosed are salts of nucleoside analogs and methods of forming the salts. An anion of a nucleoside analog is paired with a permanent counter cation to form a salt that has decreased melting point and increased aqueous solubility compared to the nucleoside compound prior to the salt formation. Also a cation of a nucleoside analog is paired with a permanent counter anion to form a salt that has decreased melting point and increased aqueous solubility compared to the nucleoside compound prior to the salt formation. The nucleoside analog in some embodiments has therapeutic activity such as antiviral. The permanent counter cation or anion in some embodiments has bioactivity such as antibacterial or being a vitamin.

    摘要翻译： 公开了核苷类似物的盐和形成盐的方法。 核苷类似物的阴离子与永久性抗衡阳离子配对以形成与盐形成之前的核苷化合物相比具有降低的熔点和增加的水溶性的盐。 核苷类似物的阳离子与永久性抗衡阴离子配对，以形成与盐形成之前的核苷化合物相比具有降低的熔点和增加的水溶性的盐。 一些实施方案中的核苷类似物具有治疗活性，例如抗病毒药物。 在一些实施方案中，永久性抗衡阳离子或阴离子具有生物活性，例如抗菌剂或维生素。